Federal Register / Vol. 62, No. 169 / Tuesday, September 2, 1997 / Notices 46373

Frequency of Use: Once per investor

per project.

Type of Respondents: Business or

other institutions (except farms);

individuals.

Standard Industrial Classification

Codes: All.

Description of Affected Public: U.S.

companies or citizens investing

overseas.

Reporting Hours: 4 hours per project.

Number of Responses: 15 per year.

Federal Cost: $300 per year.

Authority for Information Collection:

Sections 231, 234(a), 239(d), and 240A

of the Foreign Assistance Act of 1961,

as amended.

Abstract (Needs and Uses): The

application for the contractors and

exporters program is the principal

document used by OPIC to determine

the investor’s and project’s eligibility,

assess the environmental impact and

developmental effects of the project,

measure the economic effects for the

United States and the host country

economy, and collect information for

underwriting analysis.

Dated: August 26, 1997.

James R. Offutt,

Assistant General Counsel, Department of

Legal Affairs.

[FR Doc. 97–23137 Filed 8–29–97; 8:45 am]

BILLING CODE 3210–01–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[DEA # 167P]

Controlled Substances: Proposed

Aggregate Production Quotas for 1998

AGENCY: Drug Enforcement

Administration (DEA), Justice.

ACTION: Notice of proposed aggregate

production quotas for 1998.

SUMMARY: This notice proposes initial

1998 aggregate production quotas for

controlled substances in Schedules I

and II of the Controlled Substances Act.

DATES: Comments or objections must be

received on or before October 2, 1997.

ADDRESSES: Send comments or

objections to the Administrator, Drug

Enforcement Administration,

Washington, DC 20537, Attn.: DEA

Federal Register Representative (CCR).

FOR FURTHER INFORMATION CONTACT:

Frank L. Sapienza, Chief, Drug and

Chemical Evaluation Section, Drug

Enforcement Administration,

Washington, DC 20537, Telephone:

(202) 307–7183.

SUPPLEMENTARY INFORMATION: Section

306 of the Controlled Substances Act

(21 U.S.C. 826) requires that the

Attorney General establish aggregate

production quotas for each basic class of

controlled substance listed in Schedules

I and II. This responsibility has been

delegated to the Administrator of the

DEA by § 0.100 of Title 28 of the Code

of Federal Regulations. The

Administrator, in turn, has redelegated

this function to the Acting Deputy

Administrator pursuant to § 0.104 of

Title 28 of the Code of Federal

Regulations.

The quotas are to provide adequate

supplies of each substance for: (1) The

estimated medical, scientific, research,

and industrial needs of the United

States; (2) lawful export requirements;

and (3) the establishment and

maintenance of reserve stocks.

In determining the proposed 1998

aggregate production quotas, the Acting

Deputy Administrator considered the

following factors; (1) Total actual 1996

and estimated 1997 and 1998 net

disposals of each substance by all

manufacturers; (2) estimates of 1997

year-end inventories of each substance

and of any substance manufactured

from it and trends in accumulation of

such inventories; (3) product

development requirements of both bulk

and finished dosage form

manufacturers; (4) projected demand as

indicated by procurement quota

applications filed pursuant to § 1303.12

of Title 21 of the Code of Federal

Regulations and (5) other pertinent

information.

Pursuant to § 1303.23(c) of Title 21 of

the Code of Federal Regulations, the

Acting Deputy Administrator of the

DEA will, in early 1998, adjust aggregate

production quotas and individual

manufacturing quotas allocated for the

year based upon 1997 year-end

inventory and actual 1997 disposition

data supplied by quota recipients for

each basic class of Schedule I or II

controlled substance.

Therefore, under the authority vested

in the Attorney General by section 306

of the Controlled Substances Act of

1970 (21 U.S.C. 826), delegated to the

Administrator of the DEA by § 0.100 of

Title 28 of the Code of Federal

Regulations, and redelegated to the

Acting Deputy Administrator pursuant

to § 0.104 of Title 28 of the Code of

Federal Regulations, the Acting Deputy

Administrator hereby proposes that the

aggregate production quotas for 1998 for

the following controlled substances,

expressed in grams of anhydrous acid or

base, be established as follows:

Basic class Proposed

1998 quotas

Schedule I

2,5-Dimethoxyamphetamine ................................................................................................................................................................ 15,000,100

2,5-Dimethoxy-4-ethylamphetamine (DOET) ....................................................................................................................................... 2

3-Methylfentanyl ................................................................................................................................................................................... 14

3-Methylthiofentanyl ............................................................................................................................................................................. 2

3,4-Methylenedioxyamphetamine (MDA) ............................................................................................................................................. 25

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) .............................................................................................................................. 30

3,4-Methylenedioxymethamphetamine (MDMA) .................................................................................................................................. 20

3,4,5-Trimethoxyamphetamine ............................................................................................................................................................ 2

4-Bromo–2,5-Dimethoxyamphetamine ................................................................................................................................................ 2

4-Bromo–2,5-Dimethoxyphenethylamine (2-CB) ................................................................................................................................. 2

4-Methoxyamphetamine ....................................................................................................................................................................... 100,100

4-Methylaminorex ................................................................................................................................................................................. 2

4-Methyl–2,5-Dimethoxyamphetamine (DOM) .................................................................................................................................... 2

5-Methoxy–3,4-Methylenedioxyamphetamine ..................................................................................................................................... 2

Acetyl-alpha-methylfentanyl ................................................................................................................................................................. 2

Acetylmethadol ..................................................................................................................................................................................... 7

Allylprodine ........................................................................................................................................................................................... 2

Alpha-acetylmethadol ........................................................................................................................................................................... 7

Alpha-ethyltryptamine .......................................................................................................................................................................... 2
46374 Federal Register / Vol. 62, No. 169 / Tuesday, September 2, 1997 / Notices

Basic class Proposed

1998 quotas

Alphameprodine ................................................................................................................................................................................... 2

Alpha-methadol .................................................................................................................................................................................... 2

Alpha-methylfentanyl ............................................................................................................................................................................ 2

Alphaprodine ........................................................................................................................................................................................ 2

Alpha-methylthiofentanyl ...................................................................................................................................................................... 2

Aminorex .............................................................................................................................................................................................. 7

Beta-acetylmethadol ............................................................................................................................................................................ 2

Beta-hydroxyfentanyl ........................................................................................................................................................................... 2

Beta-hydroxy-3-methylfentanyl ............................................................................................................................................................ 2

Beta-methadol ...................................................................................................................................................................................... 2

Betaprodine .......................................................................................................................................................................................... 2

Bufotenine ............................................................................................................................................................................................ 2

Cathinone ............................................................................................................................................................................................. 9

Codeine-N-oxide .................................................................................................................................................................................. 2

Diethyltryptamine ................................................................................................................................................................................. 2

Difenoxin .............................................................................................................................................................................................. 16,000

Dihydromorphine .................................................................................................................................................................................. 7

Dimethyltryptamine .............................................................................................................................................................................. 2

Ethylamine Analog of PCP .................................................................................................................................................................. 5

Heroin .................................................................................................................................................................................................. 2

Hydroxypethidine ................................................................................................................................................................................. 2

Lysergic acid diethylamide (LSD) ........................................................................................................................................................ 57

Mescaline ............................................................................................................................................................................................. 7

Methaqualone ...................................................................................................................................................................................... 17

Methcathinone ...................................................................................................................................................................................... 11

Morphine-N-oxide ................................................................................................................................................................................. 2

N-Ethylamphetamine ............................................................................................................................................................................ 7

N-Hydroxy-3,4-Methylenedioxyamphetamine ...................................................................................................................................... 4

N,N-Dimethylamphetamine .................................................................................................................................................................. 7

Noracymethadol ................................................................................................................................................................................... 2

Norlevorphanol ..................................................................................................................................................................................... 2

Normethadone ..................................................................................................................................................................................... 7

Normorphine ........................................................................................................................................................................................ 7

Para-fluorofentanyl ............................................................................................................................................................................... 2

Pholcodine ........................................................................................................................................................................................... 2

Psilocin ................................................................................................................................................................................................. 2

Psilocybin ............................................................................................................................................................................................. 2

Tetrahydrocannabinols ......................................................................................................................................................................... 26,000

Thiofentanyl .......................................................................................................................................................................................... 2

Trimeperidine ....................................................................................................................................................................................... 2

Schedule II

1-Phenylcyclohexylamine ..................................................................................................................................................................... 15

1-Piperidinocyclohexanecarbonitrile (PCC) ......................................................................................................................................... 12

Alfentanil .............................................................................................................................................................................................. 8,100

Amobarbital .......................................................................................................................................................................................... 12

Amphetamine ....................................................................................................................................................................................... 3,580,000

Cocaine ................................................................................................................................................................................................ 550,100

Codeine (for sale) ................................................................................................................................................................................ 56,334,000

Codeine (for conversion) ..................................................................................................................................................................... 18,460,000

Desoxyephedrine ................................................................................................................................................................................. 1,332,000

1,300,000 grams of levodesoxyephedrine for use in a non-controlled, non-prescription product and 32,000 grams for methamphetamine.

Dextropropoxyphene ............................................................................................................................................................................ 109,500,000

Dihydrocodeine .................................................................................................................................................................................... 189,000

Diphenoxylate ...................................................................................................................................................................................... 1,600,000

Ecgonine .............................................................................................................................................................................................. 651,000

Ethylmorphine ...................................................................................................................................................................................... 12

Fentanyl ............................................................................................................................................................................................... 202,000

Glutethimide ......................................................................................................................................................................................... 2

Hydrocodone (for sale) ........................................................................................................................................................................ 13,908,000

Hydrocodone (for conversion) ............................................................................................................................................................. 3,000,000

Hydromorphone ................................................................................................................................................................................... 766,000

Isomethadone ...................................................................................................................................................................................... 12

Levo-alpha-acetylmethadol (LAAM) ..................................................................................................................................................... 356,000

Levomethorphan .................................................................................................................................................................................. 2

Levorphanol ......................................................................................................................................................................................... 15,000

Meperidine ........................................................................................................................................................................................... 9,311,000

Methadone (for sale) ............................................................................................................................................................................ 3,790,000

Methadone (for conversion) ................................................................................................................................................................. 1,169,000

Methadone Intermediate ...................................................................................................................................................................... 6,777,000

Methamphetamine (for conversion) ..................................................................................................................................................... 723,000

Methylphenidate ................................................................................................................................................................................... 14,442,000
Federal Register / Vol. 62, No. 169 / Tuesday, September 2, 1997 / Notices 46375

Basic class Proposed

1998 quotas

Morphine (for sale) ............................................................................................................................................................................... 10,654,000

Morphine (for conversion) .................................................................................................................................................................... 75,918,000

Nabilone ............................................................................................................................................................................................... 2

Noroxymorphone (for sale) .................................................................................................................................................................. 25,000

Noroxymorphone (for conversion) ....................................................................................................................................................... 2,117,000

Opium .................................................................................................................................................................................................. 615,000

Oxycodone (for sale) ........................................................................................................................................................................... 8,393,000

Oxymorphone ...................................................................................................................................................................................... 120,000

Pentobarbital ........................................................................................................................................................................................ 16,562,000

Phencyclidine ....................................................................................................................................................................................... 60

Phenmetrazine ..................................................................................................................................................................................... 2

Phenylacetone ..................................................................................................................................................................................... 10

Secobarbital ......................................................................................................................................................................................... 301,000

Sufentanil ............................................................................................................................................................................................. 700

Thebaine .............................................................................................................................................................................................. 9,580,000

The Acting Deputy Administrator

further proposes that aggregate

production quotas for all other

Schedules I and II controlled substances

included in §§ 1308.11 and 1308.12 of

Title 21 of the Code of Federal

Regulations be established at zero.

All interested persons are invited to

submit their comments and objections

in writing regarding this proposal. A

person may object to or comment on the

proposal relating to any of the abovementioned substances without filing

comments or objections regarding the

others. If a person believes that one or

more of these issues warrant a hearing,

the individual should so state and

summarize the reasons for this belief.

In the event that comments or

objections to this proposal raise one or

more issues which the Acting Deputy

Administrator finds warrant a hearing,

the Acting Deputy Administrator finds

warrant a hearing, the Acting Deputy

Administrator shall order a public

hearing by notice in the Federal

Register, summarizing the issues to be

heard and setting the time for the

hearing.

The Office of Management and Budget

has determined that notices of aggregate

production quotas are not subject to

centralized review under Executive

Order 12866. This action has been

analyzed in accordance with the

principles and criteria contained in

Executive Order 12612, and it has been

determined that this matter does not

have sufficient federalism implications

to warrant the preparation of a

Federalism Assessment.

The Acting Deputy Administrator

hereby certifies that this action will

have no significant impact upon small

entities whose interests must be

considered under the Regulatory

Flexibility Act, 5 U.S.C. 601 et seq. The

establishment of annual aggregate

production quotas for Schedules I and II

controlled substances is mandated by

law and by international treaty

obligations. Aggregate production

quotas apply to approximately 200 DEA

registered bulk and dosage form

manufacturers of Schedules I and II

controlled substances. The quotas are

necessary to provide for the estimated

medical, scientific, research and

industrial needs of the United States, for

export requirements and the

establishment and maintenance of

reserve stocks. While aggregate

production quotas are of primary

importance to large manufacturers, their

impact upon small entities is neither

negative nor beneficial. Accordingly, the

Acting Deputy Administrator has

determined that this action does not

require a regulatory flexibility analysis.

Dated: August 25, 1997.

James S. Milford,

Acting Deputy Administrator.

[FR Doc. 97–23224 Filed 8–29–97; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Foreign Claims Settlement

Commission

Meetings

[F.C.S.C. Meeting Notice No. 20–97]

The Foreign Claims Settlement

Commission, pursuant to its regulations

(45 CFR part 504) and the Government

in the Sunshine Act (5 U.S.C. 552b),

hereby gives notice in regard to the

scheduling of meetings and oral

hearings for the transaction of

Commission business and other matters

specified, as follows:

Dates and Times: Tuesday, September 2,

1997, 9:30 a.m. to 5:00 p.m.; Wednesday,

September 3, 1997, 9:30 a.m. to 5:00 p.m.;

Thursday, September 4, 1997, 9:30 a.m. to

5:00 p.m.; Friday, September 5, 1997, 9:30

a.m. to 5:00 p.m.; Monday, September 8,

1997, 9:30 a.m. to 5:00 p.m.; Tuesday,

September 9, 1997, 9:30 a.m. to 5:00 p.m.;

Wednesday, September 10, 1997, 9:30 a.m. to

5:00 p.m.; Thursday, September 11, 1997,

9:30 a.m. to 5:00 p.m.; Friday, September 12,

1997, 9:30 a.m. to 5:00 p.m.; Monday,

September 15, 1997, 9:30 a.m. to 5:00 p.m.;

Tuesday, September 16, 1997, 9:30 a.m. to

5:00 p.m.; Wednesday, September 17, 1997,

9:30 a.m. to 5:00 p.m.; Thursday, September

18, 1997, 9:30 a.m. to 5:00 p.m.; and Friday,

September 19, 1997, 9:30 a.m. to 5:00 p.m.

Subject Matter: (1) Consideration of

Individual Proposed Decisions on Claims of

Holocaust Survivors Against Germany; (2)

Oral Hearings and Hearings on the Record on

Objections to Individual Proposed Decisions

on Claims of Holocaust Survivors Against

Germany; (3) Issuance of Individual Final

Decisions on Claims of Holocaust Survivors

Against Germany

Status: Closed.

All meetings are held at the Foreign claims

Settlement Commission, 600 E Street, NW.,

Washington, DC. Requests for information, or

advance notices of intention to observe an

open meeting, may be directed to:

Administrative Officer, Foreign Claims

Settlement Commission, 600 E Street, NW.,

Room 6002, Washington, DC 20579.

Telephone: (202) 616–6988.

Dated at Washington, DC, August 27, 1997.

Judith H. Lock,

Administrative Officer.

[FR Doc. 97–23279 Filed 8–27–97; 4:23 pm]

BILLING CODE 4410–01–P

DEPARTMENT OF JUSTICE

Immigration and Naturalization Service

Agency Information Collection

Activities: Proposed Collection;

Comment Request

ACTION: Revision of existing collection;

Generic Clearance of Customer Service

Surveys.

The Department of Justice,

Immigration and Naturalization Service

(Service) has submitted the following

information collection request (ICR) for

review and clearance in accordance

with the Paperwork Reduction Act of